EUKEMIA INHIBITORY factor (LIF) was purified'.2
L and cloned3 on the basis of its capacity to induce differentiation in and suppress the proliferation of the MI murine myeloid leukemic cell line. Human LIF was subsequently shown to have comparable effects on human HL60 and U937 cells, particularly when acting in collaboration with colony-stimulating factor^.^ LIF, when acting alone, has no apparent proliferative effects on cultured normal murine hematopoietic cells,' although it does stimulate the proliferation of the continuous hematopoietic cell line DAI6 and erythroid cell lines from myc-transformed cells from mouse fetal liver (Maekawa T, Cory S, Metcalf D, unpublished data, November 1989). Receptors for LIF are present on monocyte-macrophage^,^ and some nonhematopoietic cells including osteoblasts, placental trophoblasts, and liver parenchymal cells. ' LIF has been shown to possess a remarkable variety of actions. It releases calcium from bone tissue,' and is the differentiation inhibitory factor preventing spontaneous differentiation in normal embryonic stem cells,'0." HILDA, a molecule stimulating DAI cell proliferation: the hepatocyte stimulating factor I11 stimulating liver cells to produce acute-phase protein^,'^." the cholinergic neuronal differentiation factor,14 and a lipoprotein lipase inhibitor. '' In initial studies, the consequences of high LIF levels were compensatory splenic and liver extramedullary hematopoiesis, a neutrophil leukocytosis, pancreatitis, calcification in skeletal muscle, heart, and liver, liver necrosis, and fibrosis, thymus atrophy, adrenal cortex changes, and gonadal dysgenesis.
The engraftment model is potentially complex due to the presence of the engrafted FDC-P1 cells so, in the present experiments, purified recombinant murine LIF was injected into mice to determine what changes could be induced.
MATERIALS AND METHODS
Mice. Mice used were specific pathogen-free 2-to 3-month-old females of the strain DBA/2 (the strain previously used as recipients of LIF-producing FDC-PI cells) and the endotoxin-hyporesponsive strain, C3H/HeJ, the latter to minimize the possibility that any observed changes might be ascribable to endotoxin.
Recombinant murine LIF was produced using the pGEX bacterial expression system" and purified to homogeneity as described previo~sly.'~ The specific activity of the LIF was lo8 U/mg protein (50 U/mL is the concentration inducing the differentiation of 50% of MI colonies in agar cultures of 300 MI leukemic cells).
The recombinant LIF was diluted in 5% fetal calf serum in 0.9% NaCl (FCS/saline) so that each dose injected was in a volume of 0.2 mL. Control mice were injected with 0.2 mL of the same 5% FCS/saline diluent batch. Two separate preparations of LIF were used and two different batches of FCS/saline used as diluent. All preparations were assayed by the Limulus amebocyte lysate assay (Commonwealth Serum Laboratories, Melbourne, Australia) and the injection volumes of 0.2 mL of LIF in FCS/saline or 0.2 mL FCS saline were found to contain 0.1 to 0.2 ng endotoxin, indicating that the endotoxin content of the material probably originated from the FCS used.
Mice were injected intraperitoneally 1 to 3 times daily for up to 14 days with 0.2 mL of LIFor FCS/saline, weighed at intervals, and then analyzed in detail on the morning after completion of the last day of injections.
Mice were anesthetized and orbital plexus blood used for white blood cell (WBC), hematocrit, and platelet estimations. The mice were then exsanguinated from the axillary vessels and the serum diluted 1:4 in 0.9% NaCl for further analysis. Peritoneal cavity cells were collected using 2 mL of 5% FCS/saline, organs were weighed, and total femur cell counts performed. Cytocentrifuge preparations were made from peritoneal, spleen, and marrow cells and stained with May-Griinwald Giemsa. All preparations were scored using coded slides. Organs were fixed in 10% formal saline, sectioned, and stained with hematoxylin and eosin or Recombinant LIF.
Injections.
Observations. for reticulum. Spleen and marrow cell suspensions were cultured to determine the frequency of progenitor cells using 1-mL agarmedium cultures of 25,000 cells stimulated by a mixture of 400 U granulocyte-macrophage colony-stimulating factor (GM-CSF) and 400 U multi-CSF.*' After 7 days of incubation, colony counts were performed, and the cultures fixed with 1 mL of 2.5% glutaraldehyde and stained for acetylcholinesterase then with Lux01 Fast Blue and hematoxylin. Differential colony counts on coded preparations were performed" at 200 x magnifications.
Erythrocyte sedimentation was measured in heparinized capillary hematocrit tubes using a 50-mm column of blood. Accelerated sedimentation of red blood cells was noted within 10 minutes with blood from LIF-injected mice, but measurements were made routinely after 2 hours. For simplicity, the figures were transformed arithmetically to millimeter of sedimentation per 100-mm column.
Serum calcium and albumin estimations were performed using 1:4 diluted serum and kits supplied by Trace Scientific (Melbourne, Australia).
Megakaryocyte cell counts were performed at 400x magnifications from coded sections of spleen and sternal marrow segments. The area surveyed was determined from camera lucida drawings, and the figures expressed as megakaryocytes x area-' x organ weight for spleen, or megakaryocytes x area-' x 100 for individual sternal marrow segments.
Assays for GM-CSF or multi-CSF in serum were performed using serial twofold dilutions of serum in microwell cultures of 200 FDC-PI cells, according to techniques described previously." Sera were assayed for the presence of inhibitors by mixing with standard preparations of purified GM-CSF and multi-CSF of known biologic activity.
All data were analyzed using the Student's t-test to establish the statistical significance of observed differences.
RESULTS

Statistical analysis.
The mean serum LIF concentrations in mice engrafted with LIF-producing FDC-P1 cells approximated 1,000 U/ mL.16*'7 To determine if comparable concentrations could be achieved by the injection of LIF, studies were performed on the serum half-life of LIF injected intravenously or intraperitoneally. Intravenous injection of 2 pg (2 x lo5 U) of L I F resulted in a very short serum half-life with a second phase of 8 to 9 minutes (data not shown). However, the intraperitoneal injection of 2 pg LIF resulted in a sustained elevation of serum LIF levels that exceeded 1,000 U/mL for approximately 3 hours (Fig I) . On this basis, the initial studies were performed using 2 pg LIF injected intraperitoneally three times daily at 8 AM, 2 PM, and 5 PM. In subsequent experiments, lower doses of LIF were used and the number of injections per day varied from 1 to 3.
The dose of 2 pg LIF three times daily appeared to be close to the toxic limit because deaths occurred at day 3 of the smallest of 16 DBA/2 mice, between days 5 and 9 of 4 of 8 possibly abnormal C3H/HeJ mice, and on day 5 of the smallest of another group of 8 C3H/HeJ mice.
At this dose level, a uniform effect of injected LIF in mice of both strains in five separate experiments was an initial weight loss, evident by day 2 and progressive during the first week of injections, but with no further weight loss during the second week (Fig 2) . Accompanying the weight loss was a curious state of hypermobility and irritability of the mice, with the hair on the back of the neck being erect. No fighting was exhibited. The LIF-injected mice also showed difficulty in recovering from methoxyfluorane, the anesthetic used.
No deaths or weight loss occurred in mice injected with 200 ng or lower doses of LIF, administered 1 to 3 times daily for 14 days, and no irritability of behavior was observed at these dose levels.
The changes observed at day 15 in mice injected with 2 pg LIF three times daily are summarized in Table 1 . No significant changes occurred in total WBCs, but a small decrease in hematocrit was observed in LIF-injected mice. A notable finding was an increase in platelet levels of almost 100% in LIF-injected mice. Platelet levels were not elevated at 6 to 24 hours after a single injection of 2 pg LIF or after 3 days of injections of 2 pg LIF administered three times daily (Tables 1 and 2 ).
Another feature of the blood from mice injected with 2 pg L I F was an acceleration of erythrocyte sedimentation, which was noted within 3 days with injections of 2 pg LIF and a t 14 days with as low a dose regimen as 200 ng LIF, administered twice daily ( Table 2) .
As shown in the typical example in Fig 3, serum calcium levels were elevated in mice injected with 2 pg LIF for 14 days, the increases averaging 30% above values in controlinjected mice. Accompanying the increase in serum calcium was a consistent decrease in serum albumin levels, leading to an elevation in wlcium/albumin ratios. Elevated serum calcium/albumin ratios were observed with as low a dose as 20 ng administered once daily for 14 days ( the lower doses the differences were not significantly different due to variations between individual values.
In view of the elevations observed in platelet levels, the possibility was considered that LIF may have induced elevations of two factors with known in vivo actions on the megakaryocytes GM-CSF22 and multi-CSF interleukin-3 (IL-3).23 However, assays on sera from LIF-injected mice failed to detect either factor, and no inhibitors were observed that might have blocked their detection.
Marrow, spleen, and peritoneal cell changes. Table 3 summarizes data from DBA/2 mice injected with 2 pg LIF three times daily for 14 days. For brevity, similar data from C3H/HeJ mice have not been detailed.
A uniform finding in mice of both strains was a decrease of approximately 40% in total marrow cell numbers, with a significant decrease in the percentage of lymphoid cells and a small, but significant, increase in the percentage of mature granulocytes.
A minor weight increase was observed in the spleen of LIF-injected mice and, as shown in Table 3 , in LIF-injected mice there was a significant decrease in the percentage of lymphocytes and significant increases in the percentages of nucleated erythroid cells and mature granulocytes.
Some variability was encountered between experiments in the total numbers of peritoneal cells in LIF-injected mice, with no consistent trend being obvious. Injection of FCS/ saline induced the appearance of significant numbers of eosinophils, possibly as a result of the repeated injection of foreign protein, and the response only became evident during the second week of injections. This eosinophil response was significantly lower or absent in LIF-injected mice. Conversely, LIF-injected mice exhibited a significant elevation in the percent of lymphocytes in peritoneal populations.
In all of the above parameters, the changes observed in C3H/HeJ mice injected with 2 kg LIF were identical in direction and also statistically significant, but usually were slightly smaller in magnitude.
In DBA/2 mice injected with 200 ng LIF 1 to 3 times daily, comparable but less marked changes in bone marrow cellularity were observed, interestingly, spleen enlargement was more evident than with higher LIF doses ( Table 2) .
Megakaryocyte changes. Because megakaryocytes were not adequately represented in cytocentrifuge preparations, counts of megakaryocyte numbers were made from sections of the spleen and sternal marrow segments. In both strains injected three times daily with 2 pg LIF for 14 days, the frequency of megakaryocytes was significantly increased in the spleen two-to fivefold (Table 4, Fig 4) and significant elevations of lesser magnitude were observed in the sternal marrow.
Significant elevations of spleen megakaryocyte numbers were detectable (threefold) with as little as 20 ng LIF injected once daily for 14 days, and some elevation of megakaryocyte numbers in the spleen was noted within 3 days of injecting 2 kg LIF three times daily ( Table 2) . Progenitor cell changes in marrow and spleen. The frequency of progenitor cells (exclusive of megakaryocyte progenitors) was significantly higher in the bone marrow of DBA/2 and C3H/HeJ mice injected with 2 pg LIF three times daily for 14 days than in the marrow of control-injected mice (Fig 5) . However, when these values were corrected for the decrease in total marrow cellularity, total progenitor cell numbers were essentially unaltered by LIF injections.
In contrast, a marked increase in the frequency of progenitor cells was observed in the spleen of both strains injected with LIF. Because the overall size of the spleen was slightly increased, this indicates a rise in the absolute numbers of progenitor cells. Differential colony counts showed no differences between LIF-injected and control mice in the relative frequencies of the various subsets of progenitor cells: granulocytic, granulocyte-macrophage, macrophage, eosinophil, erythroid, and mixed-erythroid progenitors.
The frequency of megakaryocyte colonies is not shown in the data in Fig 5, and counts were performed independently on acetylcholinesterase-stained cultures to determine their frequency. The frequency of megakaryocyte progenitors was significantly higher in the marrow of LIF-injected mice than in control mice, and 10-fold higher in the spleen of LIF-injected mice than in control mice (Table 4) . When corrected for absolute cell numbers, there was little absolute increase in megakaryocyte progenitors in the marrow, but the increases were a t least 10-fold in the spleen.
In mice injected with 2 p g LIF three times daily for 14 days, examination showed that the loss of body weight was ascribable to complete loss of subcutaneous and intraabdominal fat, a change that became evident after only 3 days of injections.
Other changes in LIF-injected mice.
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Liver and kidney weights were unaltered, suggesting that the weight loss was not a true cachexia.
Mice receiving these doses of LIF exhibited pronounced thymus atrophy ( Table 2 ) due to complete loss of cortical lymphocytes. No thymus weight loss was observed in mice injected with lower doses of LIF.
A curious finding observed in 10 of 14 C3H/HeJ mice, but not in DBA/2 mice injected 3 times daily with 2 r g LIF for 3 to 14 days, was a grossly distended stomach with pylorospasm. The small bowel and colon were narrowed, with increased muscle tone. The stomach contained food and the bowel and colon contained apparently normal fecal material.
The liver showed no evidence of infiltration by hematopoietic cells, no increase in resident Kupffer cells, and no calcification. Small foci of calcium deposition were observed in the myocardium of 8 of 11 DBA/2 mice injected with 2 pg LIF versus 4 of 12 control mice, a slight but not significant difference. No myocardial calcification was observed in any C3H/HeJ mouse injected with LIF.
No histologic abnormalities were noted in the pancreas, ovaries, adrenal cortex, or skeletal muscle comparable with those present in mice engrafted with LIF-producing cells."'~"
In view of the marked excess new bone formation in mice engrafted with LIF-producing FDC-PI cell^,'^^" an analysis was made of the femur, tibia, and sternum. No obvious new bone formation was observed in the femur or tibia as assessed in particular by unusual trabeculae formation. However, analysis of sternal segments indicated some thickening of the bone cortex in LIF-injected DBA/2 mice. In mice injected with 2 pg LIF 3 times daily for 14 days, the area occupied by bone cortex was 30.4% * 4.2% of the total area of sternal segments versus 23.1% * 5.6% in control mice (P < .01).
However, in C3H/HeJ mice given the same LIF dosage the figures were only 23.1% 2 5.3% versus 21.4% f 4.4, not a significant difference.
DISCUSSION
The very short serum half-life of intravenously injected LIF indicated that the intraperitoneal route was more practicable in mice for ensuring sustained periods of elevated serum LIF levels. Irradiated mice engrafted with LIFproducing cells developed serum levels averaging 1 O3 U/mL, and some developed organ changes within 14 days.l6.l7 The initial schedule chosen to document in vivo effects of intraperitoneally injected LIF was 2 pg three times daily for 14 days, which would achieve LIF levels above lo3 U/mL for several hours after each injection. The toxicity and deaths encountered suggest that these were near-lethal doses.
The hematopoietic changes observed in LIF-injected mice had a curious pattern but indicated that LIF has either direct or indirect actions affecting certain hematopoietic populations. Injections of 2 pg LIF failed to reproduce the characteristic neutrophil leukocytosis seen in the engrafted model,I7 but did reproduce other changes seen in such mice, including reduced marrow cellularity with selective loss of marrow lymphocytes, depression of spleen lymphocyte populations with increased splenic erythropoiesis, and marked thymus atrophy due to loss of cortical lymphocytes.
A clear elevation of progenitor cells was induced in the spleen by the injection of LIF, and this included increases in megakaryocyte progenitors. While the progenitor cell changes did not result in observable increases in mature neutrophils, monocytes, or eosinophils, they were associated with an increase in megakaryocyte numbers, followed by an increase in blood platelet levels. Increased spleen megakaryocytes were noted previously in the engrafted model,'7 but in this model were associated with a general rise in spleen hematopoiesis due to the prominent extramedullary hematopoiesis. The magnitude of the megakaryocyte and platelet increases induced by LIF was equal to or greater than those reported after the injection of m~l t i -C S F ,~~ thr~mbopoietin,~~ or IL-6,25 and suggests an interesting possible clinical use of recombinant LIF in the treatment of thrombocytopenias. In this context, it is of interest that reduced doses of LIF were still able to induce changes in megakaryocyte and platelet levels without toxic effects as assessed by behavioral changes, or body or thymus weight loss. LIF induced rises in megakaryocyte progenitor cells and megakaryocytes before increases in platelet levels, suggesting that the observed rises in platelets were based on the increased formation of megakaryocytes and not merely the induced release of platelets from existing megakaryocytes.
The effects of LIF in elevating levels of megakaryocytes and platelets were surprising in view of the lack of proliferative effects of LIF in clonal cultures of normal murine marrow c e h 5 This raises the possibility of an indirect effect, perhaps mediated by the induced production of IL-3 or IL-6. No IL-3 was detected in the sera, and preliminary bioassays for IL-6 using an IL-6-responsive line have indicated no differences in IL-6 levels between LIF-injected and control mice. In contrast, it has been observed in current experiments that megakaryocytes have receptors for LIF and bind injected radiolabeled LIF, and that LIF can enhance megakaryocyte colony formation in marrow cultures stimulated by multi-CSF (IL-3) (Metcalf D, Hilton DJ, Nicola NA, unpublished data, November 1989). Therefore it is possible that LIF enhances megakaryocyte formation in vivo by a direct action when acting in collaboration with other regulators.
Striking early effects of high doses of LIF were a hyperactive state and body weight loss, the latter based on a reduction in subcutaneous and abdominal fatty tissue. The hyperactive state may be related to the ability of LIF to switch autonomic nerve signaling from the adrenergic to cholinergic model4 or be a response to the hypercalcemia. The selective loss of body fat may be based on the lipoprotein lipase inhibitory activity of LIF," which may prevent the transport of lipid into fat cells. The increased erythrocyte sedimentation rate noted in LIF-injected mice was apparent within 6 hours of a single injection, and may be due to the ability of LIF to induce the production by liver cells of acute-phase protein^'^,'^ likely to influence erythrocyte sedimentation. This acute-phase response may also have been the basis for the observed decrease in serum albumin levels. No abnormalities were noted in other organs of LIFinjected mice other than minimal calcification in the myocardium, and this was seen only in some groups of mice injected with the highest doses of LIF.
One of the most striking changes in mice engrafted with LIF-producing cells was the excess osteoblast activity and new bone formation, occurring particularly in the sternum and ends of the long Marked changes of this nature were not observed in LIF-injected mice, but LIF injections possibly induced some thickening of the cortex of sternal bone segments.
The present in vivo experiments have indicated interesting effects of injected LIF on progenitor cell levels, megakaryocyte formation, and platelet levels. These effects of LIF warrant further study to determine the effects, particularly on platelet formation, of LIF combined with other hematopoietic regulators, such as GM-CSF, multi-CSF, and IL-6, which have actions on the proliferation of megakaryocyte populations.
